AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company for $320 million.
If you are not happy with the results below please do another search
50 search results for:
The agency will provide end-to-end omnichannel offering and capabilities across healthcare that will support and complement the network’s agencies and clients in the region.
England’s government agency responsible for responding to public health emergencies said mistakes at a testing laboratory resulted in tens of thousands of positive COVID-19 cases reported as negative may have led to the deaths of 20 people.
Visconti will oversee all aspects of the agency’s marketing intelligence services, leading a team of accomplished specialists who provide data, analysis, insights, multi-touch attribution models, predictive data intelligence, and success metrics for enhancing client and agency decision-making and optimizing the impact of client marketing campaigns.
The deal, valued at $615 million, will expand Boston Scientific’s portfolio of gastric devices.
The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease.
Lumanity’s deep data analytics, value demonstration, and therapeutic area expertise alongside HealthVerity’s patient identity resolution technology and leading ecosystem of interoperable real-world data enables evidence generation across the pharma lifecycle.
Healthcare ecosystem stakeholders, including pharmaceutical and device manufacturers, will continue to coalesce in support of the Quintuple Aim in 2023. This article is a preview of three SDOH trends that will expand in importance to take on pernicious challenges in 2023.
The FDA has accepted Roche and Sarepta’s Biologic License Application for the accelerated approval of SRP-9001 (delandistrogene moxeparvovec), an investigational gene therapy for Duchenne muscular dystrophy (DMD).
A Phase III trial of Axsome Therapeutics’ AXS-05 hit both the primary and secondary endpoints in patients with Alzheimer’s disease agitation, the New York-based company announced Monday.